U.S. markets closed

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.07-0.09 (-0.89%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close10.16
Open10.28
Bid9.65 x 1000
Ask11.00 x 800
Day's Range10.00 - 10.30
52 Week Range9.51 - 11.07
Volume89,830
Avg. Volume260,689
Market Cap349.825M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020
    GlobeNewswire

    Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020

    Orphazyme A/S Company announcement                                                                                        No. 67/2020                                                                                                           Company Registration No. 32266355 Copenhagen, Denmark, October 23, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein (HSP) response for the treatment of neurodegenerative orphan diseases, today announces an update to its financial outlook for 2020. The update is primarily driven by an acceleration in commercial and other pre-launch activities during the fourth quarter of 2020 in preparation for potential approval of its investigational product candidate arimoclomol in Niemann-Pick disease Type C (NPC), which is currently under Priority Review by the U.S. Food and Drug Administration (FDA) with a target action date of March 17, 2021.The increased expenditure is based on Orphazyme’s reinforced financial position following a successful global offering, as well as the FDA acceptance of its New Drug Application (NDA) for arimoclomol for NPC and granting of Priority Review. The Company also plans additional investments to further develop its pipeline.    Kim Stratton, Chief Executive Officer of Orphazyme, said, “There is real momentum here at Orphazyme as we move closer to potential approval of arimoclomol in the U.S. in its first indication of NPC and accelerating our preparatory efforts now will help ensure a smooth launch. There are currently no approved products for NPC in the US and arimoclomol has the potential to make a significant difference to patients with this devastating disease, so our team is working expeditiously to ensure we are optimally positioned for a successful launch if approved.”Full-year 2020 anticipated operating lossDKKmUSDm* Previous guidance(500) – (550)(80) – (88) New guidance(625) – (650)(96) – (104) Cash position at December 31, 2020DKKmUSDm* Previous guidance>300>48 New guidance>700>111 *USD figures are for reference only; FX rate 1 DKK / 0.16 USD.Year to date, operating expenses have tracked in line with the Company’s previous guidance of an operating loss of DKK 500 – 550M. Following the successful global offering, the company has decided to accelerate its pre-launch activities during the fourth quarter in preparation for potential approval of arimoclomol in the U.S. and will further invest in its Early Access Programs, additional API manufacturing, regulatory affairs, and clinical safety activities. Orphazyme also expects continued costs through year-end for the on-going trials in sporadic Inclusion Body Myositis and Amyotrophic Lateral Sclerosis in order to provide home nursing and direct to patient distribution due to the COVID-19 pandemic. In addition, the Company intends to increase investment in its NME program of next generation HSP amplifiers and will incur additional operational costs in Q4 2020 associated with the U.S. listing. As a result, the operating loss is expected to be in the range of DKK 625M to DKK 650M (USD 96M to USD 104M), for the fiscal year ending December 31, 2020. Orphazyme expects to finish 2020 with cash of DKK >700M (USD >111M). This compares to previous guidance of DKK >300M (USD >48M) and includes net proceeds to date from the Company’s recent global offering.In September 2020, the FDA accepted Orphazyme’s New Drug Application for arimoclomol for NPC, with Priority Review. The FDA set a target action date of March 17, 2021 under the Prescription Drug User Fee Act, or PDUFA, for completion of its review of the NDA. Orphazyme continues to expect to submit a Marketing Authorization Application, or MAA, to the European Medicines Agency in the second half of 2020. For additional information, please contactOrphazyme A/SAnders Vadsholt, CFO                                  +45 28 98 90 55 About Orphazyme A/S  Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq Copenhagen (ORPHA.CO). Forward-looking statement  This company announcement may contain certain forward-looking statements, including with respect to Orphazyme’s full year 2020 anticipated operating loss and cash position at December 31, 2020. Although Orphazyme believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond Orphazyme’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond Orphazyme’s control that could cause Orphazyme’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements, including in respect of unanticipated expenditures during the fourth quarter of 2020. Except as required by law, Orphazyme assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.Attachment * 67-2020 Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020

  • MarketWatch

    Dozens of volunteers to be deliberately infected with COVID-19 in effort to speed up vaccine development

    Young and healthy volunteers in London are to be deliberately infected with the SARS-CoV-2 coronavirus early next year, in a bid to accelerate the development of a vaccine. Experts from Imperial College London, the National Health Service and Irish company Open Orphan’s (UK:ORPH)hVivo unit will explore and establish the world’s first “human challenge trial” for COVID-19, the U.K. government said on Tuesday, as it pledged £33.6 million for the study. Human challenge studies, which have been successfully used in the past to develop vaccines for malaria and cholera, involve deliberately infecting volunteers to test the effectiveness of vaccines.

  • GlobeNewswire

    Stabilization measures taken

    Orphazyme A/S Company announcement                                                                                        No. 66/2020                                                                                                           Company Registration No. 32266355 Copenhagen, Denmark, October 16, 2020 – With reference to company announcement no. 56/2020 dated September 29, 2020 regarding beginning of the stabilization period following the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share (the “Ordinary Shares”), in the United States (the "U.S. Offering"), and a concurrent private placement of Ordinary Shares in Europe (the “European Private Placement”), Orphazyme A/S ("Orphazyme") has received notification from  BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering, that the stabilization measures set out in the attached notification have been taken. Reference is made to the attached notification from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme, with respect to the ADSs of Orphazyme traded on the Nasdaq Global Select Market in the United States and the Ordinary Shares of Orphazyme traded on Nasdaq Copenhagen A/S, respectively.This company announcement does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful and the announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdiction, prior to registration or qualification under the securities laws of any such state or jurisdiction. For additional information, please contactOrphazyme A/SAnders Vadsholt, CFO                                  +45 28 98 90 55Attachments: Notification from BofA Securities, Inc. About Orphazyme A/S  Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. Orphazyme is harnessing amplification of Heat-Shock Proteins (or HSPs) in order to develop and commercialize novel therapeutics for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction, including lysosomal storage diseases and neuromuscular degenerative diseases. Arimoclomol, Orphazyme’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme’s shares are listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.Forward-looking statement  This company announcement may contain certain forward-looking statements. Although Orphazyme believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond Orphazyme’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond Orphazyme’s control that could cause Orphazyme’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, Orphazyme assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.  Attachments * 66-2020 Stabilization measures taken * Attachments Notification from BofA Securities, Inc.